Novavax, Inc. (NVAX) Stock
NVAX Key Statistics
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
CEO: John Charles Jacobs. Company website
NVAX — Frequently Asked Questions
What is the NVAX stock price today?
Novavax, Inc. (NVAX) trades at $10.11, up 1.10% on the day, as of Sep 20, 2026 15:01 UTC.
What is Novavax, Inc.'s market cap?
Novavax, Inc. has a market capitalisation of $1.66B, calculated from the live NVAX share price and shares outstanding.
What is the P/E ratio of NVAX?
NVAX has no meaningful price-to-earnings ratio: Novavax, Inc. lost $1.52 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Novavax, Inc. make?
Novavax, Inc. generated revenue of $413.80M over the trailing twelve months, which puts the stock at 4.02 times sales.
What is the 52-week range for NVAX?
NVAX has traded between $6.20 and $11.97 over the past 52 weeks, and the last price is 15.5% below that high.
Is Novavax, Inc. profitable?
No. Novavax, Inc. is loss-making, with a net margin of -59.87% over the trailing twelve months.
What is the analyst price target for NVAX?
Wall Street analysts rate NVAX Buy, with an average price target of $18.00, 78.0% above the current price.
What sector is Novavax, Inc. in?
Novavax, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Novavax, Inc.?
John Charles Jacobs is the chief executive of Novavax, Inc., which employs 749 people.
Where can I track NVAX in real time?
QFI Terminal shows NVAX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See NVAX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open NVAX in Terminal See plans